(Q37812007)

23 August 2017

Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure (English)

1 reference

23 August 2017

0 references

3

Mihai Gheorghiade

1 reference

23 August 2017

Satyam Sarma

1

1 reference

PubMed ID

21104312

23 August 2017

Hossein Ardehali

series ordinal

2

1 reference

23 August 2017

1 January 2012

1 reference

23 August 2017

Heart Failure Reviews

1 reference

23 August 2017

17

1 reference

23 August 2017

1

1 reference

23 August 2017

35-43

1 reference

https://scigraph.springernature.com/pub.10.1007/s10741-010-9208-0

23 August 2017

0 references

cites work

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Cardiac-resynchronization therapy for the prevention of heart-failure events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

The failing heart--an engine out of fuel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Energy metabolism of the heart: from basic concepts to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Myocardial substrate metabolism in the normal and failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Metabolic mechanisms in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferator-activated receptor alpha but not gamma activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Nuclear receptors and the control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Cardiac peroxisome proliferator-activated receptor-alpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9208-0

Effects of Fenofibrate on Cardiac Remodeling in Aldosterone-Induced Hypertension

21 January 2018

1 reference

12 December 2020

Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy

1 reference

12 December 2020

Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha is downregulated in the failing human heart

1 reference

12 December 2020

Myocardial substrate metabolism influences left ventricular energetics in vivo

1 reference

12 December 2020

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

1 reference

12 December 2020

Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure

1 reference

12 December 2020

Fatty acid oxidation enzyme gene expression is downregulated in the failing heart

1 reference

12 December 2020

Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions

1 reference

12 December 2020

Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure

1 reference

12 December 2020

Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors

1 reference

12 December 2020

Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report

1 reference

12 December 2020

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

1 reference

12 December 2020

An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts

1 reference

12 December 2020

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

1 reference

12 December 2020

First clinical trial with etomoxir in patients with chronic congestive heart failure

1 reference

12 December 2020

A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation

1 reference

12 December 2020

A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated wi

1 reference

12 December 2020

Inhibition of fatty acid oxidation and decrease of oxygen consumption of working rat heart by 4-bromocrotonic acid

1 reference

12 December 2020

Dissociation between gene and protein expression of metabolic enzymes in a rodent model of heart failure

1 reference

12 December 2020

Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart.

1 reference

12 December 2020

Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir

1 reference

12 December 2020

10.1007/S10741-010-9208-0

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21104312